WELKOM,   Inloggen   |   Registreren Trivano op Facebook Trivano op Twitter Volg Trivano via RSS  
Grafiek MDxHealth (ex. OncoMethylome Sciences)MDxHealth (ex. OncoMethylome Sciences)

MDXH | BE0003844611
Euronext Brussel
1,500 EUR   (2,04%)

Hoogste 12m: 1,87 EUR
Laagste 12m: 1,25 EUR
Beleg goedkoper met Lynx
Kosten order 3.000 EUR: 6,00 EUR
Toevoegen aan Mijn Selectie   Aandeel toevoegen aan Mijn selectie
Samenvatting Profiel Dividend Kerncijfers Insiders Nieuws Persberichten Agenda Grafiek Koersen

Persberichten

Nieuws via RSS voor MDxHealth (ex. OncoMethylome Sciences)
23 mei 2012MDxHealth’s ConfirmMDx™ for Prostate Cancer Test Helps to Identify Men Able to Avoid Repeat Biopsies
16 mei 2012MDxHealth Provides First Quarter 2012 Business Update
15 mei 2012MDxHealth Launches ConfirmMDx for Prostate Cancer
26 april 2012MDxHealth and PLUS Diagnostics Enter U.S. Marketing Agreement for ConfirmMDx for Prostate Cancer
15 maart 2012MDxHealth Reports Fourth Quarter and Year End 2011 Financial Results
23 januari 2012MDxHealth Receives CLIA Certification and California State License for its Clinical Laboratory
09 januari 2012MDxHealth Receives 2011 European Molecular Diagnostics for Oncology Technology Leadership Award
14 december 2011Meta-Analysis Confirms Link Between Epigenetic Changes and Prostate Cancer, Reports MDxHealth
07 december 2011MDxHealth Enters Agreement with University Hospital of Bonn for Use of the Epigenetic MGMT test in Phase III Brain Cancer Study
02 december 2011MDxHealth Enters Agreement with Celldex for Use of MGMT Epigenetic Test in Phase III Rindopepimut Study in Brain Cancer
17 november 2011MDxHealth Provides Third Quarter 2011 Business Update
15 november 2011MDxHealth Reports Positive Results for its Prostate Cancer Diagnostic Test
27 september 2011MDxHealth Confirms Progress on Companion Diagnostics Partnering
25 augustus 2011MDxHealth Reports 2011 Half-Year Results
18 augustus 2011MDxHealth establishes US CLIA laboratory in Irvine, CA, and makes key hires to expand US team
03 augustus 2011MDxHealth's biomarker part of large pivotal colon cancer trial initiated by Exact Sciences
11 juli 2011MDxHealth's MGMT Test Shown to Be Only Prognostic Factor in Journal of Clinical Oncology Report on Newly Diagnosed Brain Cancer Patients
23 juni 2011Extraordinary General Shareholders' Meeting
09 juni 2011MDxHealth and Merck KGaA extend Agreement for use of MGMT Assay in Brain Cancer Clinical Trials
06 juni 2011MDxHealth's MGMT Test Identifies Brain Cancer Patients Likely to Live Longer on Temozolomide Treatment - Phase III Data Presented at ASCO

Oudere persberichten »